SLC5A8 has been shown to be associated with a large number of cancer progressions. However, the biological functions of SLC5A8 in hepatocellular carcinoma (HCC) remain largely unclear. Therefore, we performed this research to explore the functions of SLC5A8 in HCC progression. In this study, SLC5A8 protein and mRNA expression were examined by immunohistochemistry and quantitative real-time PCR, respectively, and we found significantly lower expression levels in HCCs than in the corresponding normal liver tissues. Low SLC5A8 expression was significantly correlated with the clinicopathological features of HCC patients. Patients with low SLC5A8 expression have a shorter overall survival time. This interpretation is confirmed by the results obtained from our in vitro experiments; functional assays indicated that overexpression of SLC5A8, by infection with a recombinant plasmid containing SLC5A8, significantly suppressed HCC cell growth, invasion, and migration and induced HCC cell apoptosis. Moreover, the expression levels of beta-catenin, cyclin D1, c-Myc, MMP-2, and FAK detected by western blotting were downregulated in SLC5A8-transfected HCC cells compared with control-transfected cells, indicating that SLC5A8 has a tumor-suppressive function that acts by interfering with Wnt/β-catenin signaling in HCC.
SLC5A8 Hepatic cancer Biomarker Prognosis Wnt/β-catenin signaling
This is a preview of subscription content, log in to check access.
This project was supported by the Jiangsu Provincial Natural Science Foundation of China (Grant No. BK20131095).
Gopal E, Miyauchi S, Martin PM, Ananth S, Roon P, Smith SB, et al. Transport of nicotinate and structurally related compounds by human SMCT1 (SLC5A8) and its relevance to drug transport in the mammalian intestinal tract. Pharm Res. 2007;24:575–84. doi:10.1007/s11095-006-9176-1.CrossRefPubMedGoogle Scholar
Porra V, Ferraro-Peyret C, Durand C, Selmi-Ruby S, Giroud H, Berger-Dutrieux N, et al. Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J Clin Endocrinol Metab. 2005;90:3028–35. doi:10.1210/jc.2004-1394.CrossRefPubMedGoogle Scholar
Ueno M, Toyota M, Akino K, Suzuki H, Kusano M, Satoh A, et al. Aberrant methylation and histone deacetylation associated with silencing of SLC5A8 in gastric cancer. Tumour Biol. 2004;25:134–40. doi:10.1159/000079145.CrossRefPubMedGoogle Scholar
Park JY, Zheng W, Kim D, Cheng JQ, Kumar N, Ahmad N, et al. Candidate tumor suppressor gene SLC5A8 is frequently down-regulated by promoter hypermethylation in prostate tumor. Cancer Detect Prev. 2007;31:359–65. doi:10.1016/j.cdp.2007.09.002.CrossRefPubMedGoogle Scholar
Park JY, Helm JF, Zheng W, Ly QP, Hodul PJ, Centeno BA, et al. Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic cancer. Pancreas. 2008;36:e32–9.CrossRefPubMedGoogle Scholar
Paroder V, Spencer SR, Paroder M, Arango D, Schwartz S, Mariadason JM, et al. Na(+)/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: molecular characterization of SMCT. Proc Natl Acad Sci U S A. 2006;103:7270–5. doi:10.1073/pnas.0602365103.CrossRefPubMedPubMedCentralGoogle Scholar
Liu WB, Liu JY, Ao L, Zhou ZY, Zhou YH, Cui ZH, et al. Epigenetic silencing of cell cycle regulatory genes during 3-methylcholanthrene and diethylnitrosamine-induced multistep rat lung cancer. Mol Carcinog. 2010;49:556–65. doi:10.1002/mc.20621.CrossRefPubMedGoogle Scholar